COMPARATIVE ANALYSIS OF QUANTITATIVE COMPUTED TOMOGRAPHY DATA AND HISTOLOGICAL FINDINGS IN PATIENTS WITH GIANT CELL BONE TUMOR TREATED WITH DENOSUMAB
Background. Giant cell tumor of bone (GCTB) is a common benign lesion accounting for 4–9.5 % of all primary bone tumors. Although surgery is considered the method of choice in the treatment of GCT, however, denosumab, a genetically engineered drug with a novel mechanism of action, has been recently...
Principais autores: | S. A. Tabakaev, I. G. Frolova, I. I. Anisenya, N. V. Vasilyev, A. V. Bogoutdinova, P. K. Sitnikov |
---|---|
Formato: | Artigo |
Idioma: | Russian |
Publicado em: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2021-05-01
|
coleção: | Сибирский онкологический журнал |
Assuntos: | |
Acesso em linha: | https://www.siboncoj.ru/jour/article/view/1751 |
Registros relacionados
-
Denosumab in irresectable giant cell tumour of the cervical spine
por: Ntumsi A. Tontu, et al.
Publicado em: (2024-08-01) -
Effects of Neoadjuvant Denosumab on Radiological and Histological Responses in Patients Undergoing En Bloc Resection for Giant Cell Tumor of Bone: A Systematic Review
por: Hendra Aditama, et al.
Publicado em: (2024-10-01) -
Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
por: DENO Research Group, et al.
Publicado em: (2025-01-01) -
Clinical Outcome of Extended Curettage with Postoperative Denosumab Administration for the Treatment of Campanacci Grade III Giant Cell Tumors of the Extremities
por: Zhang S, et al.
Publicado em: (2024-12-01) -
USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES
por: Tamise da Silva Baptista, et al.
Publicado em: (2019-01-01)